AIM's Clinical Strategy Under Incumbent Board Has Totally Failed
AIM ImmunoTech(AIM) GlobeNewswire News Room·2024-12-11 20:30
Incumbent Board’s Claims of Progress Are Not Credible or Supported by DataAIM Maintains Relationship with CRO Co-Founded by a Convicted Felon Who Deceived Investors about the Timeline and Status of Regulatory Submissions to the U.S. FDAAccording to ISS – “The lack of transparency gives the impression that the company’s pipeline is more advanced and that the company is more involved than it actually is”1 Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with StockholdersKellner Group Urges ...